Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib plus temozolomide in progressive lung and gastroenteropancreatic neuroendocrine neoplasms
2020-001898-78Phase 2Terminated
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Oct 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib and temozolomide in apudoma (NET), bronchial neuroendocrine tumor, gastroenteropancreatic neuroendocrine tumor (GEP-NET) and 1 more, sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Overall response rate. Started Oct 2020; status: terminated.
02
Drugs
cabozantinibtemozolomide
03
Conditions
apudoma (NET)bronchial neuroendocrine tumorgastroenteropancreatic neuroendocrine tumor (GEP-NET)multiple endocrine neoplasia (MEN)
Beyond the preview
Go deeper on 2020-001898-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001898-78.